AU2004229392A1 - Tie-2 modulators and methods of use - Google Patents

Tie-2 modulators and methods of use Download PDF

Info

Publication number
AU2004229392A1
AU2004229392A1 AU2004229392A AU2004229392A AU2004229392A1 AU 2004229392 A1 AU2004229392 A1 AU 2004229392A1 AU 2004229392 A AU2004229392 A AU 2004229392A AU 2004229392 A AU2004229392 A AU 2004229392A AU 2004229392 A1 AU2004229392 A1 AU 2004229392A1
Authority
AU
Australia
Prior art keywords
triazol
pyridin
ethyl
methyloxy
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004229392A
Other languages
English (en)
Inventor
Jeff Chen
Lisa Dalrymple
Sergey Epshteyn
Timothy Forsyth
Tai Huynh
James Leahy
Grace Mann
Larry W. Mann
Brian Ridgway
Joan C. Sangalang
Craig Takeuchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of AU2004229392A1 publication Critical patent/AU2004229392A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2004229392A 2003-04-09 2004-04-08 Tie-2 modulators and methods of use Abandoned AU2004229392A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46147103P 2003-04-09 2003-04-09
US60/461,471 2003-04-09
PCT/US2004/010626 WO2004091480A2 (en) 2003-04-09 2004-04-08 Tie-2 modulators and methods of use

Publications (1)

Publication Number Publication Date
AU2004229392A1 true AU2004229392A1 (en) 2004-10-28

Family

ID=33299820

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004229392A Abandoned AU2004229392A1 (en) 2003-04-09 2004-04-08 Tie-2 modulators and methods of use

Country Status (6)

Country Link
US (1) US8178570B2 (https=)
EP (1) EP1611123B8 (https=)
JP (1) JP4881725B2 (https=)
AU (1) AU2004229392A1 (https=)
CA (1) CA2520255C (https=)
WO (1) WO2004091480A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200533357A (en) * 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
US20080096848A1 (en) * 2004-09-29 2008-04-24 Cytovia Inc. Substituted N-Aryl-9-Oxo-9H-Fluorene-1-Carboxamides and Analogs as Activators of Caspases and Inducers of Apoptosis
MX2007004781A (es) 2004-10-20 2007-05-11 Applied Research Systems Derivados de 3-arilamino piridina.
ES2373912T3 (es) * 2005-01-28 2012-02-10 Novartis Ag Uso de pirimidilaminobenzamidas para el tratamiento de enfermedades que responden a la modulación de la actividad de quinasa tie-2.
ZA200807263B (en) * 2006-04-19 2009-11-25 Serono Lab Novel heteroaryl-substituted arylaminopyrldine derivatives as MEK inhibitors
CL2008000986A1 (es) 2007-04-06 2008-10-17 Neurocrine Biosciences Inc COMPUESTO DERIVADO DE HETEROCICLOS DE NITROGENO, AGONISTAS DEL RECEPTOR GnRH; COMPOSICION FARMACEUTICA QUE COMPRENDE A DICHO COMPUESTO; Y USO PARA TRATAR UNA AFECCION RELACIONADA CON LAS HORMONAS SEXUALES, ENDOMETRIOSIS, DISMENORREA, ENFERMEDAD DE OV
PE20090044A1 (es) 2007-04-06 2009-01-23 Neurocrine Biosciences Inc Antagonistas del receptor de la hormona liberadora de gonadotropina y procedimientos relacionados con los mismos
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
EP2307456B1 (en) 2008-06-27 2014-10-15 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
JO3078B1 (ar) 2009-11-27 2017-03-15 Janssen Pharmaceutica Nv مورفولينوثيازولات بصفتها منظمات الوستيرية نوع الفا 7 موجبة
JP2013147428A (ja) * 2010-04-27 2013-08-01 Dainippon Sumitomo Pharma Co Ltd 新規２−ヘテロアリール単環ピリミジン誘導体
EP2708537A4 (en) * 2011-05-10 2014-10-01 Taisho Pharmaceutical Co Ltd HETEROAROMATIC RING DERIVATIVE
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
AU2014233363B2 (en) * 2013-03-15 2017-06-29 EyePoint, Inc. Compositions, formulations and methods for treating ocular diseases
JP2015131783A (ja) * 2014-01-14 2015-07-23 株式会社日本ファインケム アリール−１，２，４−トリアゾール誘導体の製造方法
US9598381B2 (en) * 2014-07-31 2017-03-21 Abbvie Inc. SMYD2 inhibitors
US11352326B2 (en) 2016-11-16 2022-06-07 The General Hospital Corporation Myeloperoxidase imaging agents
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
CN114072205A (zh) * 2019-04-18 2022-02-18 视点制药公司 用tie-2激活剂治疗高血压的方法
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
TW202115024A (zh) 2019-08-14 2021-04-16 美商英塞特公司 作為cdk2 抑制劑之咪唑基嘧啶基胺化合物
AU2020364007A1 (en) 2019-10-11 2022-04-28 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MC598A1 (fr) * 1966-02-16 1967-03-21 Mauvernay Roland Yves Nouveaux composés chimiques et procédé pour leur préparation
IL31990A (en) * 1968-04-26 1974-05-16 Chinoin Gyogyszer Es Vegyeszet Pyridyl 1,2,4-oxadiazole derivatives,process for the preparation thereof and pharmaceutical compositions containing same
US3978054A (en) * 1974-11-29 1976-08-31 Merck & Co., Inc. 1,3,5-Trisubstituted-1,2,4-triazole compounds
AR230994A1 (es) 1981-08-31 1984-08-31 Pfizer Procedimiento para preparar compuesto de 3'-substituido-5'-(2-amino-4-piridil)-1',2',4'-triazol
GB8829296D0 (en) * 1988-12-15 1989-01-25 Ici Plc Anti-tumour compounds
JPH0813446B2 (ja) * 1990-05-30 1996-02-14 株式会社日立製作所 スリツプキヤステイング法
JP3217846B2 (ja) * 1992-03-04 2001-10-15 クミアイ化学工業株式会社 トリアゾール誘導体及び殺虫剤
WO2002032896A1 (en) 2000-10-16 2002-04-25 Novo Nordisk A/S Furazanyl-triazole derivates for the treatment of diseases
JP2004532234A (ja) 2001-04-27 2004-10-21 バーテックス　ファーマシューティカルズ　インコーポレイテッド トリアゾール由来キナーゼインヒビターおよびその使用
KR20040004705A (ko) * 2001-06-08 2004-01-13 시토비아 인크. 카스파제의 활성제 및 아폽토시스의 유도제로서의 치환된3-아릴-5-아릴-[1,2,4]-옥사디아졸과 유사체 및 이의 용도
US20050004186A1 (en) * 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
JP2007223901A (ja) * 2004-03-24 2007-09-06 Takeda Chem Ind Ltd 複素環化合物およびその用途

Also Published As

Publication number Publication date
JP4881725B2 (ja) 2012-02-22
EP1611123B1 (en) 2013-10-02
CA2520255C (en) 2014-07-08
EP1611123B8 (en) 2013-11-13
WO2004091480A3 (en) 2005-08-11
JP2006522813A (ja) 2006-10-05
EP1611123A2 (en) 2006-01-04
CA2520255A1 (en) 2004-10-28
EP1611123A4 (en) 2008-07-02
US20060293342A1 (en) 2006-12-28
US8178570B2 (en) 2012-05-15
WO2004091480A2 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
US8178570B2 (en) Tie-2 modulators and methods of use
EP1663204B1 (en) C-kit modulators and methods of use
AU2004230928B2 (en) Tie-2 modulators and methods of use
US7846959B2 (en) Raf modulators and methods of use
JP4901102B2 (ja) プロテインキナーゼモジュレーターおよびその使用方法
CA2541989C (en) P70s6 kinase modulators and method of use
US8710038B2 (en) Pyrazole kinase modulators and methods of use
JP2006505509A (ja) 受容体型キナーゼモジュレーターおよびその使用方法
CN108779110A (zh) 磷脂酰肌醇3-激酶γ的新颖抑制剂
CN101166719A (zh) Bcrp/abcg2抑制剂
KR20230035311A (ko) Nek7 키나제의 억제제
US8013156B2 (en) Tie-2 modulators and methods of use
JPH04235983A (ja) 新規キノリン誘導体およびそれを有効成分として含有する制癌剤効果増強剤

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period